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Capillary reversed-phase liquid chromatography was coupled to electrospray ionization mass 
spectrometry for determining the concentration of human serum albumin (HSA) in a fresh 
frozen serum reference material. A biotinylated HSA (bHSA) was prepared and used as an 
internal standard for the serum albumin determination. The average HSA concentration f the 
serum sample was determined by mass spectrometry to be 41.5 + 2.8 g/L  at the 95% 
confidence limit for the measured value. The HSA concentration f the fresh frozen serum was 
also assayed using the bromocresol green dye-binding method, producing avalue of 42.3 + 1.5 
g/L. Calibration curves generated from HSA standards piked with bHSA showed excellent 
linearity and the relative standard eviation for replicate analysis of a bHSA spiked serum 
sample was less than 3%. (J Am Soc Mass Spectrom 1997, 8, 1247-1254) 
F 
or many clinical analytes, a range of assays from 
a multitude of manufacturers is available for use. 
A consequence of this diversity is often variability 
of assay results from one analysis to the next or from 
one laboratory to the other. Discrepancies will often 
result in additional testing, driving up health care costs 
and adding additional risk to the patient. For some 
clinical analytes, cholesterol being an example, an ex- 
tensive reference system has been developed that facil- 
itates the comparability ofresults from various methods 
and permits laboratories to evaluate critically their 
performance [1]. These reference systems utilize defin- 
itive and/or  reference methods, i.e., methods for mea- 
suring a particular analyte which give results that are 
accepted as the nearest attainable to the true values, and 
whose accuracy can be demonstrated on theoretical 
grounds [2,3]. These methods are used to certify analyte 
concentrations in reference materials that laboratories 
and manufacturers can then use for calibration and 
control of their methods, promoting method compara- 
bility. However, for many analytes, particularly large 
biomolecules, reference systems have not been estab- 
lished primarily because definitive and/or  reference 
methods do not exist. Without this measurement infra- 
structure, existing methods often produce widely vary- 
ing results. 
Definitive and/or  reference methods for the clinical 
analysis of biomolecules require high specificity be- 
cause of the complexity of the serum or urine matrix 
that is common for clinical samples. Highly specific 
methods such as isotope dilution mass spectrometry 
(IDMS) have been used in many definitive and refer- 
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ence methods for a variety of small organic and inor- 
ganic serum analytes of clinical interest [4]. Recently, 
Barr et al. [5] demonstrated the use of IDMS for the 
quantitation of apolipoprotein A-l, a human serum 
protein with an approximate relative molecular mass 
(Mr) of 28,000. Their approach included the enzymatic 
digestion of apolipoprotein A-1 into small peptides, 
followed by the determination f one of the peptides by 
liquid chromatography/mass spectrometry (LC/MS) 
by using an isotopically labeled peptide as internal 
standard. While this approach produced excellent 
quantitative results on a sample of pure, lyophilized 
protein, it would not be practical for the determination 
of a protein in a complex matrix such as serum. The 
isolation and purification steps needed prior to analysis 
of a protein in a complex matrix necessitate he use of a 
protein internal standard to minimize the impact of 
sample loss on the accuracy of the determination. IDMS 
is not practical for the analysis of an intact protein 
because of the extensive amount of isotope label that 
would be required to distinguish the internal standard 
from the native protein if a low resolution mass ana- 
lyzer, such as a quadrupole, were used. 
With the introduction of ionization methods uch as 
electrospray ionization (ESI) and matrix assisted laser/ 
desorption ionization (MALDI), the qualitative analysis 
of large proteins has become routine, providing molec- 
ular mass information with more accuracy, precision, 
and sensitivity than any other method. Thus far, the 
preponderance of protein and peptide determinations 
using mass spectrometry have used MALDI-MS [6-9]. 
Although, to the best of our knowledge, no quantitative 
analysis of proteins has been reported using ESI-MS, 
this technique has been used for the quantitation of 
peptides [10-12]. For clinical samples in complex ma- 
Received March 31, 1997 
Revised July 20,/997 
Accepted July 21, 1997 
1248 BUNK AND WELCH J Am Soc Mass Spectrorn 1997, 8, 1247-1254 
trices, ESI-MS offers the advantage of its ability to be 
directly coupled to separation techniques such as liquid 
chromatography (LC) or capillary electrophoresis. By 
separating the analyte from its matrix, the coupling of a 
separation step to ESI-MS can provide higher specificity 
than ESI-MS alone, reducing the chance of interference 
by sample matrix components. In the study presented 
here, we have used LC/ESI-MS for the determination f 
human serum albumin (HSA) in a serum reference 
material. HSA, the most abundant protein in adult 
plasma, transports a chemically diverse collection of 
both endogenous and exogenous ligands throughout 
the bloodstream and maintains plasma osmotic pres- 
sure [13]. Decreased serum albumin concentrations are 
observed in a number of clinical disorders including 
malnutrition, tissue damage and inflammation, and 
diabetes [14]. Determination of HSA in a clinical labo- 
ratory setting is usually based on its binding to the 
anionic dyes bromocresol green (BCG) or bromocresol 
purple (BCP). We undertook this study to explore the 
quantitative capabilities of ESI-MS for the analysis of a 
large protein in a "real world" matrix, conditions in 
which a clinical reference method would be expected to 
perform. This study evaluates the precision and accu- 
racy of ESI-MS for the determination f HSA in a serum 
reference material and is the first study of its kind that 
uses this technique for protein quantitation. 
Experimental 
Materials 
HSA standards were obtained from United States Bio- 
chemical (Cleveland, OH, lot #74147 and #54618), and 
Sigma Chemical Co. (St. Louis, MO, lot #124H6130) and 
were used without further purification. Fresh frozen 
serum (produced in 1994) was obtained from a com- 
mercial source. Solvents for chromatography were 
HPLC grade from J. T. Baker (Phillipsburg, NJ). The 
trifluoroacetic acid (TFA) used for the reversed-phase 
liquid chromatography was obtained from Pierce 
(Rockford, IL). 
Preparation of Internal Standard 
For use as an internal standard for HSA quantitation, 
pure HSA was biotinylated at Cys-34, the site of the 
protein's one free thiol, using a thiol-specific biotinylat- 
ing reagent. Approximately 53.6 mg of HSA standard 
(United States Biochemical, lot #74147) was dissolved in 
0.1 mol/L phosphate buffer, pH 7.0 containing 5 
mmol/L  ethylenediaminetetraacetic acid (EDTA) to 
produce a 2.5 g/L  HSA solution. A thiol-reactive bioti- 
nylating reagent, 1-biotinamido-4-[4-(maleimidometh- 
yl)cyclohexanecarboxamido] butane (biotin-BMCC) 
from Pierce, was dissolved in dimethyl sulfoxide at a 
concentration of 4.5 mg/mL. Approximately 1.2 mL of 
the biotin-BMCC solution was added to the HSA solu- 
tion and the reaction was allowed to proceed for 90 min 
at room temperature in the dark. The protein was 
precipitated from the solution by the addition of two 
volumes of ice-cold ethanol. The precipitated protein 
was collected by centrifugation and redissolved in 
phosphate buffered saline (PBS). To remove any resid- 
ual biotin-BMCC, the HSA solution was dialyzed over- 
night against PBS by using an 8000 molecular mass 
cut-off dialysis tubing. Biotinylated HSA (bHSA) was 
separated from native (unreacted) HSA by using avi- 
din-affinity chromatography with Ultralink immobi- 
lized monomeric avidin column (Pierce) according to 
the manufacturer's specifications. 
Liquid Chromatography-Electrospray Ionization 
Mass Spectrometry 
Mass spectra were recorded on a Finnigan MAT (San 
Jose, CA) TSQ-70 triple quadrupole mass spectrometer 
upgraded with a TSQ-700 operating system and 
equipped with an Analytica (Branford, CT) electrospray 
source. In the positive ion mode, mass spectra were 
obtained by scanning the first quadrupole from 1000 
m/z to 2000 m/z in 2 s at a sampling rate of 5 data 
points per mass unit. 
Samples were introduced into the electrospray 
source by capillary reversed-phase high performance 
liquid chromatography (HPLC) by using a 0.32 mm × 
1200 mm column packed with Vydac Cs, 30 nm pore 
size (The Separations Group, Hesperia, CA). The capil- 
lary column was slurry-packed with the aid of a stain- 
less steel pressure vessel [15] pressurized to 8300 kPa 
with helium. An Ultra-Plus binary gradient micro-LC 
pump (Microtech Scientific, Sunnyvale, CA) was used 
to produce the solvent gradients needed for the capil- 
lary reversed-phase HPLC. Chromatographic solvent A 
was an aqueous solution containing 0.05% TFA and 
10% acetonitrile; solvent B was acetonitrile containing 
0.05% TFA and 10% water. The solvent gradient started 
at 25% solvent B and was held there for 5 min before 
increasing to 70% solvent B after 35 min and then to 
90% solvent B after 45 min. The pump was operated at 
40/xL/min, but a column flow rate of 1-2/xL/min was 
obtained by preinjector flow splitting. A Rheodyne 
(Cotati, CA) model 7520 injector with a 1 p,L rotor was 
used. 
Preparation of HSA Standards and Serum Samples 
An approximate 45 g/L  HSA solution in water was 
prepared by using HSA from United States Biochemical 
(lot #74147). The protein concentration i this solution 
was determined by using the BCG dye-binding HSA 
assay (Sigma Chemical Company) by using 20, 40, and 
60 g/L  HSA standards from Sigma Chemical Company. 
HSA standard samples for LC/ESI-MS analysis were 
prepared by mixing varying volumes (5, 8, 12, and 15 
~zL) of the 45 g/L  HSA solution with approximately 348 
/~L of a 1.51 g/L  solution of bHSA in water (volumes 
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determined by weighing a gas-tight syringe before and 
after dispensing the protein solution [16]) and diluting 
to 1 mL with HPLC grade water. Serum samples for 
quantitative analysis were produced by mixing approx- 
imately 5 ~L of thawed fresh frozen serum with ap- 
proximately 176/zL of a 1.51 g /L  solution of bHSA in 
water (volumes again determined by weight) and dilut- 
ing to 500/zL with HPLC grade water. 
Data Analysis 
The charge-state ion distributions observed in ESI mass 
spectra were deconvoluted using Finnigan's BIOMASS 
software. The BIOMASS software uses the deconvolu- 
tion algorithm of Mann et al. [17]. All charge-state p aks 
in the range of 1000 m/z to 2000 m/z were used to 
obtain the deconvoluted relative molecular mass distri- 
bution. The intensity of the peaks in the deconvoluted 
relative molecular mass distribution resulting from the 
HSA in the serum or standard and the bHSA internal 
standard were ratioed by using the peak heights with- 
out any background subtraction. The ratios of the HSA 
to the bHSA peak heights in the standard samples were 
used to prepare a calibration curve from which the 
concentration of HSA in the serum samples could be 
determined. 
Bromcresol Green HSA Assay 
The determination of HSA in the fresh frozen serum 
was performed by using Sigma Diagnostics (St. Louis, 
MO) BCG reagent and the approximately 45 g /L  HSA 
standard solution prepared as described above. The 
manual assay procedure provided with the BCG re- 
agent was used. 
Results and Discussion 
In quantitative mass spectrometry, the appropriate se- 
lection of an internal standard can result in enhanced 
accuracy and precision by reducing errors due to ana- 
lyte loss during sample preparation, by correcting for 
matrix effects, and by compensating for the drifting ion 
currents of the mass spectrometer. Although stable 
isotope labeled compounds are most commonly used as 
internal standards for quantitative mass spectrometry 
of small molecules, isotopically labeled internal stan- 
dards are not practical for protein quantitation by 
ESI-MS. Quadrupole mass analyzers, commonly used 
with electrospray ionization, do not provide the resolu- 
tion needed to distinguish the native protein from one 
that has had its mass increased by a few units by the 
incorporation of an isotope label. Additionally, the 
multiple charging that is characteristic of the electros- 
pray ionization of proteins puts additional constraints 
on the mass difference that is needed to distinguish 
analyte protein and internal standard; if the mass 
difference is too large or too small, there is the potential 
for overlap of some of the peaks in the charge-state 
distributions of the two proteins. For HSA, a 1%-2% 
difference in mass between the analyte and internal 
standard proteins would be ideal. 
As an alternative to an isotopically labeled internal 
standard, we considered using an albumin from an- 
other animal species. Bovine serum albumin (BSA) is a 
logical choice as it is readily available in a highly 
purified form. Even though there are several differences 
in the amino acid sequence of BSA as compared to HSA, 
their relative molecular masses [Mr = 66, 438 --- 3 for 
HSA, My = 66,430 -+ 3 for BSA (the uncertainty is the 
standard deviation of the calculated molecular mass 
resulting from the uncertainty in the value of the 
isotopic abundance of each element)] differ by only a 
slight amount, too small to be resolved by the mass 
analyzer used in this study. Rat albumin was also 
considered as a potential internal standard for the HSA 
determination. Although the relative molecular mass of 
the rat albumin (Mr = 65,870 + 3) is substantially ess 
than that of HSA, the molecular mass distribution of rat 
albumin obtained by ESI-MS was substantially broader 
than that of HSA. Attempts at desalting the rat albumin 
sample did not reduce the width of this protein's 
molecular mass distribution. The broad molecular mass 
distribution of the rat albumin resulted in a large 
overlap of the charge-state distributions in the ESI mass 
spectrum of a mixture of rat and human albumin, 
making the rat albumin a poor choice as an internal 
standard. No other commercially available albumin, for 
which the amino acid sequence is known, has a molec- 
ular mass that differs sufficiently from that of HSA to be 
of use as an internal standard, so this approach was not 
pursued further. 
The most promising alternative for an internal stan- 
dard was a chemically derivatized version of HSA. Of 
the 35 cysteine residues in HSA, 34 are involved in 
disulfide crosslinks, leaving a free thiol on Cys-34. By 
using a thiol specific derivatizing reagent, HSA can be 
selectively derivatized at Cys-34, reducing the forma- 
tion of multiple reaction products that can make isolat- 
ing the desired reaction product difficult. The thiol 
specific reagent used, biotin-BMCC, added a biotin 
group to HSA. This biotin group provided a very 
effective "handle" through which derivatized protein 
could be separated from the native by using highly 
selective biotin-avidin chromatography [18]. With this 
approach, we were able to produce a very pure mono- 
biotinylated HSA (bHSA) for use as an internal stan- 
dard. 
The positive ion mass spectra of the albumin in a 
fresh frozen serum sample, of bHSA, and of the fresh 
frozen serum spiked with bHSA, are shown in Figure 1. 
These mass spectrum were obtained by averaging the 
ion signal under the peak attributed to the protein(s) in 
the reversed-phase LC/ESI mass chromatogram. Ions 
with charge-states ranging from +34 to +59 are ob- 
served in the m/z range of 1100 to 2000 in all three 
cases. The differences in the shape of the charge-state 
distributions observed for HSA in Figure la and bHSA 
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Figure 1. Positive ion mass spectrum of (a) HSA from fresh 
frozen serum, (b) bHSA, and (c) HSA + bHSA from a sample of 
fresh frozen serum spiked with bHSA. 
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Figure 2. The relative molecular mass distribution of (a) HSA, 
(b) bHSA, and (c) HSA + bHSA derived from the deconvolution 
of the spectra in Figure 1. 
in Figure lb are probably due to instrumental changes 
rather than a charge-state effect intrinsic to the proteins. 
There were several months between the time the spectra 
in Figures la and lb were obtained and slight changes 
to the electrospray source, usually as the consequence 
of source cleaning, were made. Slight changes in the 
capillary/skimmer distance in an electrospray source of 
the design that we used can have pronounced changes 
in the shape of protein charge state distributions. Each 
charge-state peak in the spectrum of HSA from spiked 
serum (Figure lc) is a doublet, composed of a peak at 
lower m/z from HSA and one at higher m/z from the 
internal standard, bHSA. While there is adequate reso- 
lution between most of the charge-state p aks in Figure 
lc, the HSA and bHSA peaks for each charge-state are 
not sufficiently mass resolved. Deconvolution of the 
mass spectra in Figure 1 results in the three molecular 
mass distributions shown in Figure 2. The HSA peak in 
Figure 2a has a maximum at Mr = 66,484 _+ 9 (the 
uncertainty in the measured molecular mass is the 
standard deviation from replicate measurements), 
larger than that calculated from HSA's amino acid 
sequence (M r = 66,438 + 3). This increased molecular 
mass is most likely due to the presence of covalent 
adducts to the serum albumin, such as the formation of 
mixed disulfide species with other thiol-containing 
molecules in blood like cysteine and glutathione; asym- 
metry in the HSA peak in Figure 2a, with the shoulder 
at higher molecular mass, indicates the presence of 
adduct species. Because the mass spectrometer used to 
obtain the data in Figure 2a lacks the ability to resolve 
a higher mass component from that of native HSA, the 
mass centroid (i.e., the observed Mr) of the combined, 
unresolved istributions will be observed somewhere 
inbetween the average molecular mass of HSA and that 
of the adduct species. Hence, the observation of the Mr 
of HSA at 66,484, 46 Da higher than the calculated Mr of 
the native protein, would arise from an adduct (or 
adducts) with a mass greater than 46 Da. As the data 
from which Figure 2a is derived was obtained from 
reversed-phase LC/ESI-MS, the asymmetry in the peak is 
probably not due to salt adducts, because the salt in the 
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Table 1. HSA/bHSA ESI-MS peak height ratios for replicate 
injections 
HSA/bHSA Daily mean ratio - 
Injectionnumber Peak height ratop SD 
Day 1 
Day 2 
Day 3 
1 0.929 
2 0.877 
3 0.899 
4 0.910 
5 0.914 
6 0.914 
7 0.933 
8 0.907 
9 0.934 
10 0.899 
11 0.865 
12 0.899 
13 0.908 
14 0.920 
15 0.925 
0.906 + 0.019 
0.917 _+ 0.016 
0.901 -+ 0.025 
Mean (.~) = 0 .908;  SD ((~x) = 0 .020;  RSD = 2.2%; Conf idence  l imi t  
(95%) = -+0.043. 
sermn sample would have been washed away when the 
proteins were loaded onto the reversed-phase LC column. 
The peak for the bHSA internal standard (Figure 2b) 
is centered at Mr = 66,986 + 4, slightly higher than the 
expected molecular mass (Mr = 66,972 + 3). Absent 
from the bHSA peak is the high molecular mass shoul- 
der seen for HSA. The narrower peak width of the 
bHSA would suggest that this protein does not have the 
same adducts as the HSA. Because the bHSA was 
prepared by using a thiol-specific biotinylation reagent, 
any of the HSA standard used to prepare the bHSA that 
already had covalent adducts on Cys-34 would be 
unreactive and therefore removed from the bHSA dur- 
ing purification with biotin-avidin affinity chromatog- 
raphy. Hence, the bHSA should be very homogeneous 
with respect o the chemical state of Cys-34. The in- 
creased width of the molecular mass distribution of 
HSA relative to that of bHSA suggests that the HSA has 
some chemical heterogeneity at Cys-34. 
As a consequence of the lack of mass resolution 
between the HSA and bHSA peaks (Figure lc), there is 
overlap between these peaks in the deconvoluted rela- 
tive molecular mass distribution (Figure 2c). Because of 
this overlap, we used peak heights from the deconvo- 
luted relative molecular mass distribution rather than 
peak areas to ratio the HSA signal to that of the bHSA 
internal standard. To explore how stable the analyte/ 
internal standard ratio would be by using LC/ESI-MS, 
replicate injections were performed of the same fresh 
frozen serum samples spiked with bHSA. Five injec- 
tions per day were performed for three consecutive 
days. The result of this reproducibility study is shown 
in Table 1. The values of the HSA/bHSA peak height 
ratios obtained from the deconvoluted relative molecu- 
lar mass spectra are shown for each of 15 replicate 
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Figure 3. Comparison of the relative molecular mass distribution 
of HSA from fresh frozen serum (dotted line) to those of three 
HSA standards. 
injections. The average ratio for all injections was 
0.908 _+ 0.043 at the 95% confidence limit that had a very 
low relative standard deviation (RSD) of 2.2%. There 
are no obvious trends in the data in Table 1; the average 
ratios from each of the three days of the study are 
comparable to the overall average and exhibit a steady 
level of precision. 
After evaluating the level of reproducibility that 
could be obtained by using LC/ESI-MS for a spiked 
serum sample and obtaining favorable results, this 
method was pursued for the quantitation of HSA in 
serum. To perform an HSA assay, HSA standards were 
needed. Difficulty was encountered when examining 
HSA standards from various commercial sources. Fig- 
ure 3 compares the relative molecular mass distribu- 
tions of HSA from three commercial standards to that of 
HSA from fresh frozen serum. These distributions were 
obtained by deconvoluting the mass spectra obtained 
by LC/ESI-MS. One of the HSA standards (U.S. Bio- 
chemical, lot #74147) has a relative molecular mass 
distribution that closely resembles that of the HSA from 
serum. The distributions of the other two standards are 
shifted to higher mass and are broader than that of the 
serum HSA. To be of use as a standard for HSA 
quantitation by LC/ESI-MS, the relative molecular 
mass distribution of the standard must be as close to 
that of the analyte HSA as possible to reduce overlap 
with the bHSA internal standard. Therefore, the two 
higher-mass HSA standards were not used. We did not 
try to characterize these standards any further, but have 
characterized the HSA in a freeze-dried serum sample 
that exhibited a similar relative molecular mass distri- 
bution [19]. Compared to the HSA in fresh frozen 
serum, the HSA in freeze-dried serum was found to be 
extensively glycated. It was postulated that the HSA in 
these two commercial standard materials was co- 
valently modified, either by glycation or another chem- 
ical process. The difficulties in finding a suitable HSA 
standard exemplifies the value that mass spectrometry 
can have in the quality assurance of protein standard 
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materials. There is no apparent reason why any of the 
HSA standards that were examined should differ in 
their molecular weight distributions, particularly the 
two lots from the same manufacturer, yet there does 
appear to be structural differences. Such structural 
differences could have a pronounced impact on the 
performance of an immunoassay as the binding of the 
analyte to the antibody used in the immunoassay is
sensitive to the chemical structure of the analyte. 
The three HSA calibrants for the BCG assay (at 20, 
40, and 60 g /L  HSA) could not be used for the mass 
spectrometric determination of HSA in serum because 
their molecular mass distributions were found to also 
be shifted to higher mass and wider than the distribu- 
tion of HSA from frozen serum (Figure 3). A 45 g /L  
HSA solution was prepared from the commercial HSA 
(U.S. Biochemical, lot #74147) whose molecular mass 
distribution most closely matched that of HSA from 
serum. This 45 g /L  HSA solution was used as a 
calibrant for both the mass spectrometric determination 
and the BCG HSA assay. The HSA concentration i the 
45 g /L  HSA solution was determined by using the BCG 
assay with the 20, 40, and 60 g /L  HSA calibrants. 
Therefore, the absolute accuracy of the determination of
HSA in the frozen serum by using both mass spectrom- 
etry and the BCG assay is dependent on the accuracy of 
the value assignment to the 20, 40, and 60 g /L  cali- 
brants. As we are only interested in comparing the 
values obtained by mass spectrometry to those from the 
BCG assay, it is only important hat the same HSA 
solution be used to calibrate both determinations; the 
accuracy of the HSA value of this solution is not critical 
at this stage of the method development. 
To assay HSA in fresh frozen serum, three aliquots of 
the serum were diluted and spiked with bHSA, and 
HSA standards were prepared with varying HSA/  
bHSA concentration ratios. Based on preliminary exper- 
iments, the ratios of the HSA/bHSA in the standards 
were chosen to bracket he ratios in the spiked serum 
samples, with two standards having ratios below those 
of the samples, and two above. The total ion chromato- 
gram of a serum sample spike with bHSA is shown in 
Figure 4. Due to the abundance of HSA in serum and to 
the dilution of the serum sample, HSA (and bHSA) is 
the most abundant species detected in the LC/MS 
analysis of the frozen serum samples. The HSA + bHSA 
peak exhibited good peak shape, with a slight degree of 
tailing, and no evidence that the spiked serum sample 
overloaded the capillary reversed-phase chromatogra- 
phy column. 
Each of the three spiked serum samples was ana- 
lyzed twice on nonconsecutive days, with all four 
standards analyzed on the same day as each of the 
serum samples. The results of this study are shown in 
Table 2. The average HSA concentration of the fresh 
frozen serum sample, obtained by using the data from 
all four calibration standards, was 42.0 g /L  --- 4.1 g /L  at 
the 95% confidence limit of the measured value. The 
relative standard deviation (RSD) of the average con- 
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The total ion chromatogram of a sample of fresh frozen 
centration value was 3.8%. There was no apparent 
difference between HSA concentration values obtained 
day-to-day by using the same sample or between values 
from different samples, although a larger data set is 
needed to make any assertion of measurement bias with 
more confidence. 
The four calibration standards exhibited excellent 
linearity; the squared correlation coefficients (r2) for the 
calibration curves obtained from each day of the anal- 
ysis are listed in Table 2. Averaging the six data points 
for each standard, the cumulative calibration curve 
shown in Figure 5 was obtained. This cumulative cali- 
bration curve also exhibited excellent linearity (r 2 = 
0.999) over the HSA/bHSA weight ratio range that was 
examined. The error bars on the data points in Figure 5 
represent he standard deviation of the six values 
obtained for each standard. There is a slight increase in 
the standard deviations of the average values of the 
standard's HSA/bHSA ESI-MS peak height ratios with 
increasing HSA/bHSA weight ratio. The RSDs of the 
HSA/bHSA peak height ratios range from 2.3% for the 
lowest weight ratio to 4.5% for the highest. A likely 
source of this increasing variability is the overlap be- 
tween the HSA and bHSA peaks in the ESI mass 
spectra. As the HSA concentration i creases relative to 
that of bHSA, the degree of overlap also increases. 
The equation for the cumulative calibration curve 
[y = (0.902)x + (0.367)] has a nonzero y-intercept as 
a result of the level of background intensity that is 
obtained when the ESI mass spectrum of the HSA + 
bHSA standards are deconvoluted (see, for example, 
the -20% relative intensity background in the relative 
molecular mass distribution shown in Figure 2c). If this 
background intensity is subtracted prior to the calcula- 
tion of the HSA/bHSA ratios, the y-intercept of the 
cumulative calibration curve does approach zero, but 
the variability in subtracting the background intensity 
from each distribution introduces more scatter into the 
data. Therefore, the data was analyzed without subtrac- 
tion of any background intensity. 
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Table 2. Results of the determination f HSA in fresh frozen serum 
Day 1 2 3 4 5 6 
4 point calibration: 
[HSA], g/L 43.4 40.6 44.0 40,7 40.4 42.9 
r 2 0.994 0.992 0,979 0,997 0.999 0.995 
Mean (~) = 42.0 g/L 
SD(~r x) = 1.6 g/L 
RSD = 3.8% 
Confidence limit (95%) = -+4.1 g/L 
2 point calibration: 
[HSA], g/L 
Mean (,,~) = 41.5 g/L 
SD(~r x) = 1.0 g/L 
RSD = 2.4% 
Confidence limit (95%) = -+2,8 g/L 
42.2 41.8 41.8 39.8 40.9 42.4 
In addition to using the values from all four calibra- 
tion standards, the results were recalculated by using 
only the two calibration standards whose HSA/bHSA 
values bracketed the values found for the fresh frozen 
serum samples. The HSA values obtained by using this 
bracketing, two point calibration method are also 
shown in Table 2. By using this approach, the average 
HSA concentration value (41.5 + 2.8 g/L  at the 95% 
confidence limit) was very close to that obtained by 
using all four calibration standards but with less scatter 
in the data. The RSD of the mean HSA value was 
reduced to 2.4% by using the two point calibration 
method. Bracketing, two point calibration is commonly 
used in clinical definitive and reference methods be- 
cause the approximate analyte concentration is gener- 
ally known so there is no need for the calibrants to 
cover a broad concentration range. 
To evaluate the accuracy of our HSA determination, 
the fresh frozen serum sample was also analyzed by 
using a dye-binding, spectrophotometric HSA assay. 
The same HSA standard was used here that was used to 
prepare the calibrants for the mass spectrometric deter- 
1.6 
1.5  
1 .4  
1.3 
~ 1.0 
IIi 
~ 0.9 
~I  0 .8  
0 .?  
I 
r 2 = 0.999 
, , • , , b • , . , 
0 .4  0 .5  0 .6  0 .7  0 .8  0 .9  1 .0  1.1 1 .2  
HSA/bHSA Weight Ratio 
Figure 5. Cumulative calibration curve for the determination f 
HSA in serum by LC/ESI-MS. 
ruination to calibrate the BCG HSA determination. The 
BCG assay yielded an HSA concentration for the serum 
sample of 42.3 - 1.5 g/L  at the 95% confidence limit 
(from five replicate analyses). This value is in excellent 
agreement with the value obtained by mass spectrom- 
etry. Both values are within the serum albumin concen- 
tration range of 35 to 50 g/L  expected for serum from 
healthy individuals. 
Conclusions 
Our goal was to determine whether mass spectrometry 
could be used to obtain quantitative information about 
clinically relevant proteins in serum. The quantitative 
studies of HSA in fresh frozen serum that are presented 
here indicate that LC/ESI-MS does have the necessary 
capabilities to make clinical protein measurements. De- 
spite performing measurements on a low resolution 
quadrupole mass analyzer and with an early model 
electrospray source, good measurement precision and 
accuracy were obtained. Although analysis by LC/ 
ESI-MS can be very time consuming, it was found that 
the use of a two level calibration scheme works as well 
or better than a multilevel scheme. Therefore, future 
experiments will only use two levels of calibrants, 
saving analysis time. It should be made clear that our 
efforts were not to develop a quantitative method for 
use in clinical laboratories. The intent was to develop a 
method for use in reference laboratories, uch as NIST, 
where the time it takes to make a measurement and 
sample throughout are secondary concerns to accuracy 
and precision. 
The next stage in the development ofmass spectrom- 
etry for the determination of proteins of clinical rele- 
vance is a more extensive study comparing this meth- 
odology to others that are currently being used in 
clinical laboratories. Althugh LC/ESI-MS analysis gave 
comparable results to the spectrometric, dye-binding 
HSA assay, the absolute accuracy of these methods is 
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l imited to the accuracy of the va lue ass igned to the HSA 
s tandard  used to cal ibrate them. Because we were only  
interested in compar ing  the accuracy of the mass spec- 
trometr ic  based method to the spectrophotometr ic  as- 
say, the determinat ion  of the absolute HSA concentra-  
t ion of our  p r imary  cal ibrat ion s tandard  was not  
critical. For certif ication of reference materials,  the pu-  
r ity and  concentrat ion of the HSA s tandard  must  be 
thorough ly  evaluated.  
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